HHC (Hexahydrocannabinol): Identity, Marketing and Safety Questions

Short answer

HHC (hexahydrocannabinol) is a semisynthetic cannabinoid: a lab-modified relative of THC that is sold in vapes, gummies and other products. It is not a well-studied medicine. NIDA lists HHC among intoxicating compounds with limited research on health effects. [1] This guide uses plain evidence labels: preclinical (cells/animals only), insufficient evidence, evidence of harm, mixed and marketing claim. "Proper evidence not found" means we looked and found nothing usable. For THC itself, see THC.

Identity: what the name hides

• Not the same as THC. HHC has been known since the 1940s and is a derivative of delta-9 and delta-8 THC. [2]
• Two forms (isomers). HHC products are typically sold as a mixture of isomers called 9R-HHC and 9S-HHC. [2] In a lab study of more than 60 certificates of analysis, the ratio between the two varied widely, from 0.2:1 to 2.4:1. [2]
• Why that matters. In receptor studies, 9R-HHC behaved like delta-9 THC, but 9S-HHC bound strongly with weaker activity in functional tests. [2] A separate cell study found that both forms activate CB1 only broadly like THC and each has unique properties. [3] Another assay found that the mix of HHC isomers varied between batches of seized material, and that more of the less active 9S form lowered potency. [4] Label: preclinical (cells/animals only). The same word "HHC" on two products may not mean the same effect.
• Related compounds. Products have also been found to contain HHCP (hexahydrocannabiphorol) and a by-product called dihydro-iso-THC. [5] Those are separate compounds with their own unknowns; see THCP for a related compound with a longer side chain.

Where it comes from

Lab analysis of e-cigarette cartridges found that the HHC forms present were most likely made by a reduction reaction on delta-8 or delta-9 THC. [5] This page does not describe how. HHC is therefore not a plant extract in the usual sense. We do not state that it occurs naturally in meaningful amounts, and Proper evidence not found for that in the sources read. See natural, semisynthetic and synthetic cannabinoids.

What research shows in people

• Controlled human trials. Proper evidence not found. We searched PubMed for HHC and found chemistry, forensic, survey and case-report papers, but no controlled human trial of effects or benefit.
• Use and harms survey (Ireland, 2024). In an online survey of 2,314 adults who had used drugs in the previous year, 89.9% of HHC users reported negative consequences, including anxiety or panic (14.7%) and hallucinations or psychosis (3.9%). [6] The authors note reports of psychotic illness after HHC use. [6] Label: evidence of harm signals. This was a self-reported sample of drug users, not the general public, and it does not give a risk rate.
• Driving cases. A Swedish study re-tested blood from 145 driving-under-the-influence cases that had screened positive for cannabis but negative for THC, and confirmed HHC or its breakdown products in 32. [7] It shows HHC was present in drivers, not what dose caused impairment.
• Market spread. Seizure studies in Denmark and Germany found HHC to be the most frequently identified semisynthetic cannabinoid in Denmark. [8] In German seized products, HHC content varied from below the limit of quantitation to very high levels. [9] Marketing percentages are not independent laboratory findings, and one batch is never universal.

Risks, special groups and drug tests

• Mental health. Reports link HHC use with psychotic illness. [6] Anyone with a personal or family history of psychosis or mania should avoid THC-type products unless a clinician advises otherwise; see psychosis and mania vulnerability.
• Children and pregnancy. Proper evidence not found for HHC-specific safety data in children, pregnancy or breastfeeding. See pregnancy and breastfeeding.
• Drug tests. A 2023 laboratory study found current urine immunoassay screens may detect emerging cannabinoid analogs and their metabolites; it tested HHC-related metabolites among others. [10] See cannabis and drug testing.
• Mislabeling. In an Italian study of 26 online low-THC products, 92.3% were mislabeled. [11]

Regulation (read 2026-10-22; not legal advice)

• International. At its March 2025 session the UN Commission on Narcotic Drugs added HHC to Schedule II of the 1971 Convention on Psychotropic Substances. [12] UNODC said the decision would come into force on 6 December 2025. [13] Each country decides how to apply this in its own law.
• Ireland. A 2025 paper says HHC was sold openly in Ireland as a legal alternative to cannabis products until it was controlled in July 2025. [6]
• Denmark and some EU countries. The first HHC bans in some EU countries came in early 2023. [9] Denmark scheduled HHC in May 2023. [8]
• United States. The DEA says synthetically derived tetrahydrocannabinols remain Schedule I. [14] Whether HHC falls under that wording was not verified here. A November 2025 federal hemp law, taking effect on November 12, 2026, excludes hemp products with cannabinoids made outside the plant. [15]
• Other places: not verified. See cannabis laws by country.

How to evaluate HHC claims

Look for the exact isomer ratio, a recent batch lab report, and any cited human study. "Legal", "hemp-derived" or "gentler than THC" are marketing claims unless a source is cited. Related: intoxicating hemp-derived products and the law.